Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 13Sarcoma 4Gynecologic 3Genitourinary 3Thoracic 2CNS 2Tumor-Agnostic 1Head & Neck 1Dermatologic 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Pancreatic Neoplasms 1Melanoma 1Hemangiosarcoma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 191pembrolizumab 155Pemetrexed 134Cisplatin 117durvalumab 71Paclitaxel 71osimertinib 67Nivolumab 66Docetaxel 63Specimen Handling 61atezolizumab 57Magnetic Resonance Spectroscopy 50Etoposide 46Gemcitabine 42Radiotherapy 39Radiosurgery 37130-nm albumin-bound paclitaxel 34Drug Therapy 30Cetuximab 28Bevacizumab 27Ipilimumab 25Taxes 23cemiplimab 22tislelizumab 20Platinum 20amivantamab 18Radiation 18Immunoglobulin G 171,2-diaminocyclohexaneplatinum II citrate 17Disulfides 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
balstilimab × Thoracic × 90 days × Clear all
NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Agenus Inc.

Available
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡